BBK Worldwide Announces Study eBinder 3.0
Customized Apple iPad Air Enhances Doctor-Patient Interactions in Clinical Trials
BBK Worldwide (BBK), the global leader in patient recruitment, announced today Study eBinder 3.0, the latest generation of its novel clinical trial management tool. The release of this product builds upon the success of earlier models by offering a dramatically more customized and tailored tablet experience for on-the-go study teams. Utilizing BBK's patented TrialCentralNet (TCN®) patient recruitment portal, Study eBinder 3.0 ensures compliance by providing more than 300 real-time reports and a protected instant messaging system for sponsors to connect directly with physician investigators and site staff.
"The conversation is no longer about tech adoption as today's tablet culture continues to widen," said Matt Kibby, principal, technology and innovation, BBK Worldwide. "Thirty-five percent of Americans own tablets and that number is growing. BBK was the first to translate tablets into the clinical R&D industry, ensuring clinical trial management stays top of mind."
BBK's Study eBinder 3.0 is fully customizable for both the sponsor's brand and content. With an ultimate goal of enrolling studies sooner than ever before, the metrics-driven resource is effortless to implement.
"Sites are quick to adopt this new technology," said Lucas Garmon, media strategist, BBK Worldwide. "Universal implementation of online resources across devices guarantees individuals have the most critical information at all times. From coordinating study appointments to reviewing the informed consent with patients, we have seen sites begin to rely on their ability to manage studies remotely."
Study eBinder 3.0 is also available in a restricted sponsor view, as well as a patient view, which includes condition-specific information, tips for study participation, and customized retention tools. To learn more, visit shop.BBKWorldwide.com/products/ebinder-study-ipads.
About BBK Worldwide (bbkworldwide.com)
Founded in 1983, BBK Worldwide is the recognized global leader in patient recruitment. The company is renowned for accelerating time to market for new and improved medicines and treatments. Through its partner companies, TCN Technologies and Agency320, BBK offers the industry the most sophisticated technology, creative, and media services. BBK is certified as a Safe Harbor company.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
